Data Extraction (LDH)

Overall Age High vs Unadjust Adjusted OR Length of

Authors Study Complete LDH Cut- Adjusted
No Country Subjects (Mean±SD)/ Low/Normal ed OR (95% CI) (Low Observati NOS
(Year) Design Assessment Off Value Variables
Median (n) (95% CI) vs High) on
1. Ye et al China Cohort 534 <600: Retinopathy <600, 600- <600 (no - Stage 3/4 Maternal 3-12
(2020) Retrosp 30.93±5.6 among patien 800, >800 retinopathy): retinopathy, age, in-vitro months
ective Retinopat 3 with severe 362/534 <600: reference fertilization
hy: 172 preeclampsia >800 >800: 2.31 and embryo
600-800: (retinopathy (1.05, 5.06) transfer,
No 31.50±5.5 stage 3/4): parity,
retinopat 5 78/534 multiple
hy: 362 pregnancies
>800: Delivery , gestational
31.26±5.7 gestational diabetes,
9 age preexisting
<28week: cardiovascu
<600: lar
28/362 diseases,
>800: 6/78 preexisting
renal
Placental diseases,
abruption: abnormal
<600: hematocrit,
17/362 blood urea
>800: 7/78 nitrogen,
serum
Amniotic creatinine,
fluid volume and total
disorder: bile acid.
<600:
26/362
>800: 3/78

Caesarean
section:
<600:
276/362
>800: 60/78

vaginal birth:
<600:
86/362
>800: 18/78

Postpartum
hemorrhage:
<600:
16/362
>800: 1/78

Stillbirth:
<600:
49/362
>800: 16/78

Placenta
inherence:
<600:
47/362
>800: 15/78

Placenta
accrete:
<600:
10/362
>800: 0/78

Preterm:
<600:
194/313
>800: 50/62
 Small for
gestational:
<600:
49/313
>800: 13/62

Neonatal
asphyxia:
<600:
12/313
>800: 5/62

2. Dave et al India Cohort 200 <20: 18.75% preeclampsia <600, 600- (preeclampsi - - - 3 Months
(2014) Retrosp 800, >800 a)
ective Preelamp 21-25: 62.5% <600: 5/107
sia: 32 >800: 19/57
26-30:
Eclampsi 15.625% (Eclampsia)
a: 68 <600: 2/107
>30: 3.125% >800: 38/57
Normal:
100 (normal)
<600:
100/107
>800: 0/57

(BBL <2.5)
<600:
55/107
>800: 45/57

(BBL >2.5)
<600:
52/107
>800: 12/57
(Healthy
baby)
<600:
89/107
>800: 18/57

(sick baby)
<600:
11/107
>800: 21/57

(SVD/IUD)
<600: 7/107
>800: 18/57

(Abruption)
<600: 1/107
>800: 8/57

(DIC)
<600: 0/107
>800:36/57

(ARF):
<600: 0/107
>800:5/57

(MODS)
<600: 0/107
>800: 4/57

(CVA)
<600: 0/107
>800:9/57
 (Retinopathy
)
<600: 0/107
>800: 4/57

(Shock)
<600: 0/107
>800: 5/57

(Died)
<600: 0/107
>800: 11/57
3. Kaur et al India Cohort 198 Control Complicacy of <600, 600- <600: - - - 1 year
(2016) retrospe group: pregnancy 800, >800 139/198
ctive Control 19-22: induced >800 43/198
group: 98 22.46% hypertension
23-26: Pulmonary
Study 48.97% edema:
group: 27-30: <600: 0/139
100 17.35% >800: 20/43
31-34:
10.20% Hypertensiv
>35: e
1.02% retinopathy:
<600: 2/139
Study >800: 31/43
group:
19-22: HELLP
28% syndrome:
23-26: <600: 0/139
46% >800: 1/43
27-30:
14% DIC:
31-34: 9% <600: 0/139
>35:3% >800: 1/43
 Abruptio
placebtae:
<600: 0/139
>800: 5/43

Maternal
death:
<600: 0/139
>800: 9/43
4. Vinitha et India Cohort 200 Normal: Preeclampsia <600, 600- Severe PE: - - - Until
al (2016) (?) 28.1 + 4.2 800, >800 <600: 32 labor (?)
Normal: >800: 18
Cross 100 Mild PE:
sectiona 27.3 + 3.9 Epigastric
l case Mild PE: pain:
control 121 Severe <600: 7/32
PE: >800: 14/18
Severe 23.5 + 3.3
PE: 79 Blurred
vision:
<600: 4/32
>800: 12/18

Vomiting:
<600: 12/32
>800: 15/18

Headache:
<600: 16/32
>800: 17/18

Eclampsia:
<600: 0/32
>800: 7/18

Abruptio
placenta:
<600: 0/32
>800: 4/18

Intracranial
hemorrhage:
<600: 0/32
>800: 1/18

HELLP
syndrome:
<600: 0/32
>800: 2/18

Acute renal
failure:
<600: 0/32
>800: 1/18

Pulmonary
edema:
<600: 0/32
>800: 1/18

DIC:
<600: 0/32
>800: 1/18

Perinatal
death:
<600: 2/32
>800: 14/18

Normal
vaginal
delivery:
<600: 13/32
>800: 7/18

Caesarean
section:
<600: 19/32
>800: 11/18